Skip to main content

We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.

Join Now
Sign In

Member Sign In

Username or Email Address

Password

Keep Me Signed In What does "Remember Me" do?

Don't Know Your Password?
Help

Join Now
Sign In

Member Sign In

Username or Email Address

Password

Keep Me Signed In

Don't Know Your Password?

Zacks

more

BioLineRx (BLRX)

(Delayed Data from NSDQ)

$0.61 USD

+0.04 (6.31%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $0.62 +0.01 (1.37%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Top 36% (91 out of 252)

Industry: Medical - Drugs

View All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

View Cart/Checkout

BioLineRx Ltd. [BLRX]

Reports for Purchase

Showing records 81 - 100 ( 202 total )

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 81

09/22/2016

Pages: 9

Analyst Day Recap; Assets, Data and Collaborations Drive Long Term Vision

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 82

09/22/2016

Industry Report

Pages: 30

Healthcare - The A to Z of HSCT: Investors guide to Hematopoietic Transplant Medicine

Provider: Roth Capital Partners, Inc.

Price: 75.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 83

09/21/2016

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 84

09/20/2016

Pages: 4

BL-8040/Keytruda Study Gets Going as Expected; Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 85

09/08/2016

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 86

09/08/2016

Pages: 6

Path Forward for BL-8040 Continues to Look Bright To Us; Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 87

09/07/2016

Pages: 4

BL-8040 Immunotherapy Push Forward Continues with Roche

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 88

08/12/2016

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 89

08/11/2016

Pages: 6

2Q16 Results; Projected Significant Drivers by Year-End

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 90

05/17/2016

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 91

05/17/2016

Pages: 7

1Q16 Results; Building the ''8040 Database and Regulatory Path Forward

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 92

03/30/2016

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 93

03/29/2016

Pages: 7

More Patients; Consistent Positive CR/CRi; Momentum Building

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 94

03/22/2016

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 95

03/21/2016

Pages: 13

The Year of ''8040; Imminent Phase IIa`AML Data; Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 50.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 96

03/11/2016

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 97

03/10/2016

Pages: 12

2015 Results; Imminent r/rAML ''8040 Update; Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 98

01/26/2016

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 99

01/25/2016

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 100

01/25/2016

Pages: 6

Important Visibility In Hand for BL-7010; Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party